EUVIMEDEUVIMED entdecken
Crossref

Insulin degludec

VishakhaV Jain, Omprakash Gupta

Journal of Mahatma Gandhi Institute of Medical Sciences · 2013

DOI: 10.4103/0971-9903.117795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Mahatma Gandhi Institute of Medical Sciences, 2013. Verfasst von VishakhaV Jain und 1 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitieren

Abstract (Originalsprache)

Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia. Insulin degludec is a second-generation, ultra-long-acting acylated basal insulin analogue that possesses a flat, stable glucose-lowering effect in patients with type 1 or type 2 diabetes mellitus. Findings from clinical trials have demonstrated that new-generation, once-daily basal insulin degludec provides similar A1C control as compared to insulin glargine, both administered as basal-oral therapy or in combination with insulin aspart, with the added benefits of lower rates of hypoglycemia, particularly nocturnal hypoglycemia.

Zitieren

APA

Jain, V., & Gupta, O. (2013). Insulin degludec. Journal of Mahatma Gandhi Institute of Medical Sciences. https://doi.org/10.4103/0971-9903.117795

Vancouver

Jain V, Gupta O. Insulin degludec. Journal of Mahatma Gandhi Institute of Medical Sciences. 2013. doi:10.4103/0971-9903.117795

BibTeX
@article{Jain2013,
  author = {Jain, VishakhaV and Gupta, Omprakash},
  title = {Insulin degludec},
  journal = {Journal of Mahatma Gandhi Institute of Medical Sciences},
  year = {2013},
  doi = {10.4103/0971-9903.117795}
}
Kostenlos starten →